Nxera Pharma Co., Ltd.
4565.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | ¥32 | ¥49 | ¥67 | ¥60 |
| Short-Term Investments | ¥4 | ¥0 | ¥0 | ¥0 |
| Receivables | ¥7 | ¥5 | ¥2 | ¥2 |
| Inventory | ¥9 | ¥3 | ¥0 | -¥0 |
| Other Curr. Assets | ¥6 | ¥8 | ¥1 | ¥1 |
| Total Curr. Assets | ¥58 | ¥65 | ¥70 | ¥63 |
| Property Plant & Equip (Net) | ¥7 | ¥8 | ¥4 | ¥4 |
| Goodwill | ¥26 | ¥25 | ¥15 | ¥15 |
| Intangibles | ¥52 | ¥52 | ¥9 | ¥9 |
| Long-Term Investments | ¥5 | ¥3 | ¥2 | ¥6 |
| Tax Assets | ¥4 | ¥4 | ¥1 | ¥0 |
| Other NC Assets | ¥0 | ¥0 | -¥1 | ¥0 |
| Total NC Assets | ¥94 | ¥92 | ¥29 | ¥34 |
| Other Assets | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Assets | ¥151 | ¥157 | ¥99 | ¥97 |
| Liabilities | – | – | – | – |
| Payables | ¥4 | ¥4 | ¥2 | ¥1 |
| Short-Term Debt | ¥7 | ¥7 | ¥0 | ¥0 |
| Tax Payable | ¥0 | ¥0 | ¥0 | ¥0 |
| Deferred Revenue | ¥0 | ¥0 | ¥1 | ¥1 |
| Other Curr. Liab. | ¥5 | ¥6 | ¥0 | ¥5 |
| Total Curr. Liab. | ¥16 | ¥17 | ¥4 | ¥7 |
| LT Debt | ¥61 | ¥67 | ¥30 | ¥29 |
| Deferred Rev, NC | ¥4 | ¥4 | ¥5 | ¥0 |
| Deferred Tax Liab, NC | ¥2 | ¥1 | ¥3 | ¥3 |
| Other NC Liab. | ¥1 | ¥1 | ¥0 | ¥0 |
| Total NC Liab. | ¥67 | ¥73 | ¥37 | ¥32 |
| Other Liabilities | ¥0 | ¥0 | ¥0 | ¥0 |
| Cap. Leases | ¥4 | ¥5 | ¥2 | ¥2 |
| Total Liabilities | ¥83 | ¥90 | ¥41 | ¥40 |
| Equity | – | – | – | – |
| Pref Stock | ¥0 | ¥0 | ¥0 | ¥0 |
| Common Stock | ¥47 | ¥47 | ¥41 | ¥41 |
| Retained Earnings | -¥21 | -¥16 | -¥9 | -¥10 |
| AOCI | ¥7 | ¥2 | -¥4 | -¥3 |
| Other Equity | ¥35 | ¥34 | ¥26 | ¥26 |
| Total Equity | ¥69 | ¥67 | ¥58 | ¥57 |
| Supplemental Information | – | – | – | – |
| Minority Interest | ¥0 | ¥0 | ¥0 | ¥0 |
| Total Liab. & Tot. Equity | ¥151 | ¥157 | ¥99 | ¥97 |
| Net Debt | ¥36 | ¥25 | -¥37 | -¥31 |